Skip to main content
Clinical Trials/NCT06221124
NCT06221124
Completed
Not Applicable

Ring-type Pulse Oximeter for Evaluation for Sleep Assessment Study

Belun Technology Company Limited1 site in 1 country40 target enrollmentJuly 15, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sleep-Disordered Breathing
Sponsor
Belun Technology Company Limited
Enrollment
40
Locations
1
Primary Endpoint
Validation with gold-standard polysomnography (PSG) recording
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Recently, various electronic lifestyle activity monitoring devices (ELAM) are increasingly commercially available. However, the quality and reliability of the data from ELAM are unclear, compared with polysomnography (PSG), which is the gold-standard sleep assessment method. Thus, combining ELAM with PSG will validate ELAM and improve its clinical and research utilization.

The investigators propose to conduct this study to validate ELAM device for sleep assessment. The investigators will compare Belun Ring data collection and overnight in-lab PSG measures of Sleep-Disordered Breathing (SDB) and sleep architecture in adults with obstructive sleep apnea (OSA) symptoms.

The investigators propose to recruit a total of 40 participants with symptoms of OSA. The overall accuracy, sensitivity and specificity of Belun Ring to assess SDB and sleep architecture will be validated by using PSG analysis as a gold standard.

Registry
clinicaltrials.gov
Start Date
July 15, 2020
End Date
June 12, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 18 to 80 years old. Ideally balanced for sex and age (18 to 80 years old)
  • no more than 75% of subjects in one bin of: (male, female)
  • no more than 50% of subjects in one age-group (18-29, 30-39, 40-49, 50-59, 60-80)
  • Patients with OSA symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.)
  • Without any unstable medical or psychiatric co-morbidities that would be expected to interfere with the study.
  • If taking any medication, must be on a stable dose of medication for a month
  • Able to read and understand English

Exclusion Criteria

  • Presence of any significant systemic or unstable medical condition which could lead to difficulty complying with the protocol, suicidality, current regular use of psychiatric medications, opiates, or thyroid medications, dementia, current substance abuse, post-traumatic or psychotic disorders, bipolar disorder; any significant neurologic disease, including possible and probable dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of significant head trauma, history of alcohol or substance use disorder within the past 2 years (DSM V criteria);
  • If positive airway pressure (PAP) titration study or split night study (diagnostic and PAP titration study combined)

Outcomes

Primary Outcomes

Validation with gold-standard polysomnography (PSG) recording

Time Frame: 1 year

Concordance rate of bAHI from Belun Ring and apnea-hypopnea Index (AHI) from PSG

Study Sites (1)

Loading locations...

Similar Trials